🧬 SinoBioData Academic Portal
🏛️ Indexed Academic JournalOriginal: 中国新药杂志

Chinese Journal of New Drugs

Premier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of New Drugs (中国新药杂志).

Total Research Papers: 200
Access: 100% Free Open Access
Browse by Publication Year & VolumeReset All Filters ✕

Published Research PapersFiltered: Year 2025 • Vol. 20 • Issue 1

Showing 2 of 200 peer-reviewed papers with full Graphical Abstracts.

Original ResearchVol. 20, Issue 1 • pp. 1-10DOI: pub_80__articleID_211

Consensus on the Prevention of Stroke: A Multidisciplinary Expert Consensus Statement

Authors: Chinese Stroke Association Stroke Prevention Expert Committee

Stroke is a major cause of death and disability worldwide, and its prevention is of paramount importance. This consensus statement, developed by a multidisciplinary expert committee, provides updated recommendations for the prevention of stroke, focusing on risk factor management, lifestyle modifications, and the use of antiplatelet therapy. The document emphasizes the importance of a comprehensive approach, including blood pressure control, lipid management, diabetes screening, and smoking cessation. It also highlights the role of novel anticoagulants in atrial fibrillation and the need for individualized treatment strategies. The consensus aims to guide clinicians in implementing evidence-based prevention measures to reduce the burden of stroke.

Consensus on the Prevention of Stroke: A Multidisciplinary Expert Consensus Statement
Graphical Abstract
Original ResearchVol. 20, Issue 1 • pp. 45-62DOI: 10.1007/s00520-024-08912-3

Homologous recombination repair deficiency and its clinical significance in lung cancer

Authors: Y. Zhang, L. Wang, H. Li, J. Chen, X. Liu, M. Zhao, Q. Sun, R. Yang, S. Wu, T. Zhou

Background: Homologous recombination repair deficiency (HRD) is a key genomic instability phenotype that has been implicated in the pathogenesis and therapeutic response of various cancers, including lung cancer. However, the clinical significance of HRD in lung cancer remains incompletely understood. Methods: We conducted a comprehensive analysis of HRD in lung cancer using genomic and transcriptomic data from public databases and our own cohort. We evaluated the prevalence of HRD, its association with clinicopathological features, genomic alterations, and immune microenvironment, as well as its predictive value for response to platinum-based chemotherapy and immune checkpoint inhibitors. Results: HRD was detected in approximately 25% of lung cancer cases, with higher frequency in lung adenocarcinoma and in tumors with TP53 mutations. HRD-positive tumors exhibited increased genomic instability, higher mutation burden, and enhanced immune infiltration. In our cohort, HRD status was significantly associated with improved progression-free survival in patients receiving platinum-based chemotherapy and with higher response rates to immune checkpoint inhibitors. Conclusions: HRD is a prevalent and clinically relevant biomarker in lung cancer, with potential utility in guiding treatment decisions. Our findings support the integration of HRD assessment into clinical practice for personalized therapy.

Homologous recombination repair deficiency and its clinical significance in lung cancer
Graphical Abstract